Abstract Library

#3445 The epidemiology of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in the North-East of England and a systematic review of literature

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare, slow-growing malignancies with unknown aetiology and an increasing incidence was observed globally. With limited research on GEP-NET epidemiology, the reasons behind incidence disparities across countries remain unclear. Whether this increase was a true phenomenon or confounded by factors including diagnostic advancement, environment, and classification evolution needs further enquiry.

Conference:

Presenting Author:

Authors: Chu G, Robinson S, Etherson K, McNally R,

Keywords: Gastroenteropancreatic neuroendocrine tumor, Epidemiology, Incidence,

#3273 LIBRETTO-531: Selpercatinib vs standard of care in patients (pts) with multikinase inhibitor-naïve advanced or metastatic RET-mutant (mut) medullary thyroid cancer (MTC)

Introduction: Multikinase inhibitors (MKI) are approved for MTC; however, their efficacy in RETmut MTC is limited due to incomplete RET inhibition and significant toxicity. Selpercatinib (LOXO-292), a highly selective and potent FDA approved inhibitor of RET alterations including M918T, MKI resistance-associated V804M, and others, showed robust, durable clinical activity with a tolerable profile in pts with RETmut MTC in the Phase 1/2 LIBRETTO-001 study.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Leboulleux S, Robinson B, Hoff A, Brose M, Wirth L,

Keywords: RET alteration, medullary thyroid cancer (MTC), phase 3 trial, selpercatinib,